Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2024-10-29 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
第四届监事会第三十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the supervisory board (监事会) of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the convening and attendance of the meeting and the approval of the company's 2024 third quarter report. However, the actual 2024 third quarter report is not included in this document; instead, it references that the report is disclosed on the Beijing Stock Exchange information platform. The document is short (796 characters) and serves as an announcement of the meeting resolution and approval of the quarterly report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than an Interim/Quarterly Report (IR) or Report Publication Announcement (RPA) because it contains substantive meeting resolution content rather than just a notice of report publication.
2024-10-29 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京康乐卫士生物技术股份有限公司 2024 年第三季度报告" which translates to "Beijing Kangle Weishi Biotechnology Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data for the third quarter of 2024, including consolidated and parent company balance sheets, income statements, cash flow statements, and explanations of significant changes in financial data. The document also includes sections on major events, shareholder information, and other disclosures typical of a quarterly financial report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-29 Chinese
第四届董事会第三十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 38th meeting of the 4th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes details about the meeting's time, place, attendance, and the approval of the company's 2024 third quarter report. The document explicitly states that the 2024 third quarter report has been prepared and disclosed on the Beijing Stock Exchange information platform, but the report itself is not included here. The document is short (915 characters) and serves as a meeting resolution announcement rather than the actual quarterly report. Therefore, it is best classified as a Board/Management Information (MANG) filing, which covers announcements of board meetings and decisions, including approval of financial reports.
2024-10-29 Chinese
中信证券股份有限公司关于北京康乐卫士生物技术股份有限公司向全资子公司提供担保事项的核查意见
Regulatory Filings
2024-09-10 Chinese
关于子公司申请银行授信暨公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a subsidiary applying for bank credit and the parent company providing a guarantee. It includes details about the guarantee amount, decision-making process, and opinions from the board and sponsoring institution. There are no financial statements or comprehensive financial data presented, nor is this a report or transcript. The document is a formal disclosure of a financing-related event, specifically a guarantee related to credit facilities. This fits best under Capital/Financing Update (CAP) as it concerns financing activities and guarantees provided by the company.
2024-09-10 Chinese
第四届董事会第三十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 37th meeting of the 4th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting's attendance, the approval of a proposal regarding a subsidiary's bank credit application and the company's guarantee, and voting results. There is no financial data or report content, but rather a corporate governance update about board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is short (1022 characters), and it is not a report or announcement of a report publication, but a meeting resolution announcement.
2024-09-10 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.